These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38563851)

  • 1. Real-world cost- effectiveness analysis: Tumor Treating Fields for newly diagnosed glioblastoma in China.
    Xiang Y; Chen Y; Xu Z; Zhou S; Qin Z; Chen L; Xiao D; Liu S
    J Neurooncol; 2024 Jun; 168(2):259-267. PubMed ID: 38563851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study.
    Guzauskas GF; Pollom EL; Stieber VW; Wang BCM; Garrison LP
    J Med Econ; 2019 Oct; 22(10):1006-1013. PubMed ID: 31050315
    [No Abstract]   [Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial.
    Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH
    J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients.
    Guzauskas GF; Salzberg M; Wang BC
    CNS Oncol; 2018 Jul; 7(3):CNS23. PubMed ID: 30124334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany.
    Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R
    J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.
    Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A;
    J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma?
    Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme.
    Martikainen JA; Kivioja A; Hallinen T; Vihinen P
    Pharmacoeconomics; 2005; 23(8):803-15. PubMed ID: 16097842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial.
    Toms SA; Kim CY; Nicholas G; Ram Z
    J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
    Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z
    JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
    Kovic B; Xie F
    J Clin Oncol; 2015 Jul; 33(20):2296-302. PubMed ID: 26014296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial.
    Kesari S; Ram Z;
    CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
    Connock M; Auguste P; Dussart C; Guyotat J; Armoiry X
    J Neurooncol; 2019 Jul; 143(3):605-611. PubMed ID: 31127507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study.
    Lamers LM; Stupp R; van den Bent MJ; Al MJ; Gorlia T; Wasserfallen JB; Mittmann N; Jin Seung S; Crott R; Uyl-de Groot CA;
    Cancer; 2008 Mar; 112(6):1337-44. PubMed ID: 18213621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup economic analysis for glioblastoma in a health resource-limited setting.
    Wu B; Miao Y; Bai Y; Ye M; Xu Y; Chen H; Shen J; Qiu Y
    PLoS One; 2012; 7(4):e34588. PubMed ID: 22511951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
    J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States.
    Messali A; Hay JW; Villacorta R
    Neuro Oncol; 2013 Nov; 15(11):1532-42. PubMed ID: 23935155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
    Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
    World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.